Phase I Ascending Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-986115 in Subjects With Advanced Solid Tumors

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 07 Nov 2021

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs BMS 986115 (Primary)
Indications Adenocarcinoma; Advanced breast cancer; Cholangiocarcinoma; Colon cancer; Fibroma; Gastric cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Rectal cancer; Renal cancer; Solid tumours; Thyroid cancer
Focus Adverse reactions
Sponsors Bristol-Myers Squibb

10 Apr 2018 Results assessing safety, pharmacokinetics, pharmacodynamics and preliminary anti tumor activity published in the Investigational New Drugs
30 Aug 2016 Status changed from completed to discontinued due to non-safety reason, business objectives have changed.
29 Aug 2016 Status changed from active, no longer recruiting to completed.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com